Price to Book Value (P/BV)
since 2013
Paying user area
Try for free
IQVIA Holdings Inc. pages available for free this week:
- Balance Sheet: Assets
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Long-term (Investment) Activity Ratios
- Analysis of Reportable Segments
- Analysis of Geographic Areas
- Enterprise Value (EV)
- Selected Financial Data since 2013
- Net Profit Margin since 2013
- Analysis of Revenues
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to IQVIA Holdings Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
IQVIA Holdings Inc., P/BV, long-term trends, calculation
| P/BV | = | Share price1, 2, 3 | ÷ | Book value per share1 (BVPS) | BVPS1 | = | Equity (deficit) attributable to IQVIA Holdings Inc.’s stockholders1 (in millions) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 15, 2023 | = | ÷ | = | ÷ | |||||||
| Feb 16, 2022 | = | ÷ | = | ÷ | |||||||
| Feb 12, 2021 | = | ÷ | = | ÷ | |||||||
| Feb 18, 2020 | = | ÷ | = | ÷ | |||||||
| Feb 19, 2019 | = | ÷ | = | ÷ | |||||||
| Feb 16, 2018 | = | ÷ | = | ÷ | |||||||
| Feb 16, 2017 | = | ÷ | = | ÷ | |||||||
| Feb 11, 2016 | = | ÷ | = | ÷ | |||||||
| Feb 12, 2015 | = | ÷ | = | ÷ | |||||||
| Feb 13, 2014 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of IQVIA Holdings Inc. Annual Report.
- Share Price Trend
- The share price exhibited an overall upward trend from 2014 to 2023. Beginning at $52.20 in February 2014, it increased consistently year over year, reaching a peak of $232.18 in February 2022 before slightly declining to $227.03 in February 2023. This pattern indicates strong market confidence and growth in the company's valuation over the analyzed period.
- Book Value Per Share (BVPS) Trend
- The book value per share showed notable volatility. Initially, BVPS was negative from 2014 through 2016, with values of -$5.14, -$5.66, and -$4.73 respectively. A significant positive shift occurred in 2017, when BVPS jumped to $36.62, followed by a mild increase to $38.94 in 2018. Subsequently, a gradual decline was observed from 2018 through 2023, with BVPS decreasing to $31.04 by 2023. This shift from negative to positive BVPS indicates a major improvement in net asset value at that midpoint, despite some erosion in later years.
- Price-to-Book Value Ratio (P/BV) Trend
- The P/BV ratio data is available starting 2017 and shows a rising trend over the period. The ratio increased from 2.1 in 2017 to 7.31 in 2023. This consistent rise suggests that the market price grew at a faster rate than the book value per share, reflecting increasing investor willingness to pay a premium over the net asset value. The peak P/BV ratio of 7.32 in 2022 aligns with the peak share price that year.
- Overall Insights
- The data indicates strong equity market performance, with the share price steadily increasing. The transition from negative to positive BVPS marks a significant turnaround in the company's balance sheet strength during the observed period. The increasing P/BV ratio points to elevated market expectations and possibly improved profitability or growth prospects as perceived by investors. The slight decline in share price and stabilization of P/BV in the most recent year may warrant monitoring for potential market adjustments or changes in company fundamentals.
Comparison to Competitors
IQVIA Holdings Inc., P/BV, long-term trends, comparison to competitors
| IQVIA Holdings Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 15, 2023 | |||||||||||||
| Feb 16, 2022 | |||||||||||||
| Feb 12, 2021 | |||||||||||||
| Feb 18, 2020 | |||||||||||||
| Feb 19, 2019 | |||||||||||||
| Feb 16, 2018 | |||||||||||||
| Feb 16, 2017 | |||||||||||||
| Feb 11, 2016 | |||||||||||||
| Feb 12, 2015 | |||||||||||||
| Feb 13, 2014 |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
IQVIA Holdings Inc., P/BV, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| IQVIA Holdings Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 15, 2023 | ||
| Feb 16, 2022 | ||
| Feb 12, 2021 | ||
| Feb 18, 2020 | ||
| Feb 19, 2019 | ||
| Feb 16, 2018 | ||
| Feb 16, 2017 | ||
| Feb 11, 2016 | ||
| Feb 12, 2015 | ||
| Feb 13, 2014 |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31).
Comparison to Industry (Health Care)
IQVIA Holdings Inc., P/BV, long-term trends, comparison to industry (health care)
| IQVIA Holdings Inc. | Health Care | |
|---|---|---|
| Feb 15, 2023 | ||
| Feb 16, 2022 | ||
| Feb 12, 2021 | ||
| Feb 18, 2020 | ||
| Feb 19, 2019 | ||
| Feb 16, 2018 | ||
| Feb 16, 2017 | ||
| Feb 11, 2016 | ||
| Feb 12, 2015 | ||
| Feb 13, 2014 |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31).